An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: Place in therapy

Open Access Rheumatology: Research and Reviews

Volumn 8, Issue , 2016, Pages 37-44

  Acosta Felquer, María Laura ^a   Rosa, Javier ^a   Soriano, Enrique R ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Certolizumab pegol; Efficacy; Psoriatic arthritis; Safety; Tumor necrosis factor inhibitors

Indexed keywords

CERTOLIZUMAB PEGOL;

BONE RADIOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEMATOMA; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LOADING DRUG DOSE; PATIENT SATISFACTION; PREGNANCY; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 84962463331     PISSN: None     EISSN: 1179156X     Source Type: Journal    
DOI: 10.2147/OARRR.S56837     Document Type: Review

References (56)

1. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol. 2008; 35(7): 1354-1358.
2. Soriano ER, Rosa J, Velozo E, et al. Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study. Rheumatology (Oxford). 2011; 50(4): 729-734.
3. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005; 64 Suppl 2: ii14-ii17.
4. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991; 30(4): 245-250.
5. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)-an analysis of 220 patients. Q J Med. 1987; 62(238): 127-141.
6. Ory PA, Gladman DD, Mease PJ. Psoriatic arthritis and imaging. Ann Rheum Dis. 2005; 64 Suppl 2: ii55-ii57.
7. Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis. 2006; 65(4): 478-481.
8. Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford). 2012; 51(3): 571-576.
9. Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol. 1997; 24(3): 511-517.
10. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001; 45(2): 151-158.
11. Hansen RB, Kavanaugh A. Certolizumab pegol for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2015; 11(3): 307-318.
12. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012; 71(1): 4-12.
13. Costa L, Caso F, Ramonda R, et al. Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res. 2015; 61(1-2): 147-153.
14. Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015; 74(5): 813-817.
15. Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014; 33(6): 833-839.
16. Soriano ER, Acosta-Felquer ML, Luong P, Caplan L. Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs. Best Practice Res Clin Rheumatol. 2014; 28(5): 793-806.
17. Gladman DD. Early psoriatic arthritis. Rheum Dis Clin North Am. 2012; 38(2): 373-386.
18. Acosta Felquer ML, Ferreyra Garrott L, Marin J, et al. Remission criteria and activity indices in psoriatic arthritis. Clin Rheumatol. 2014; 33(9): 1323-1330.
19. Gladman DD, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol. 2007; 34(5): 1167-1170.
20. Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014; 73(1): 238-242.
21. Soriano ER. Treatment guidelines for psoriatic arthritis. Int J Clin Rheumatol. 2009; 4: 329-342.
22. Caso F, Costa L, Del Puente A, et al. Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies. Ther Adv Chronic Dis. 2015; 6(6): 328-338.
23. Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis: Treatment recommendations for psoriatic arthritis 2015. Arthritis Rheumatol. Epub 2016 Jan 8.
24. Soriano ER. The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis. J Rheumatol Suppl. 2012; 89: 67-70.
25. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000; 356(9227): 385-390.
26. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52(10): 3279-3289.
27. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014; 73(1): 48-55.
28. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008; 35(5): 869-876.
29. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009; 60(4): 976-986.
30. Delgado Frias E, Diaz Gonzalez JF. [Certolizumab pegol]. Rheumatol Clin. 2011; 6S3: S7-S11. Spanish.
31. Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R. Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther. 2013; 7: 339-348.
32. Felquer ML, Soriano ER. New treatment paradigms in psoriatic arthritis: an update on new therapeutics approved by the U. S. Food and Drug Administration. Curr Opinion Rheumatol. 2015; 27(2): 99-106.
33. Caso F, Lubrano E, Del Puente A, et al. Progress in understanding and utilizing TNF-alpha inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2015: 1-17.
34. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007; 13(11): 1323-1332.
35. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001; 121(5): 1145-1157.
36. Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005; 21(3): 251-258.
37. Rosa J, Sabelli M, Soriano ER. Prefilled certolizumab pegol (Cimzia((®))) syringes for self-use in the treatment of rheumatoid arthritis. Med Devices (Auckl). 2010; 3: 25-31.
38. Dhillon S. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis. Drugs. 2014; 74(9): 999-1016.
39. Gladman D, Fleischmann R, Coteur G, Woltering F, Mease PJ. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care Res (Hoboken). 2014; 66(7): 1085-1092.
40. Mease P, Fleischmann R, Wollenhaupt J, et al. Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure. Arthritis Rheum. 2013; 65 (Suppl): S132.
41. Tillett W, de-Vries C, McHugh NJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology (Oxford). 2012; 51(2): 275-283.
42. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006; 54(4): 685-704.
43. Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Ann Rheum Dis. 2015; 74(1): 44-51.
44. van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014; 73(1): 233-237.
45. Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014; 73(1): 39-47.
46. Nash P, Lubrano E, Cauli A, Taylor WJ, Olivieri I, Gladman DD. Updated guidelines for the management of axial disease in psoriatic arthritis. J Rheumatol. 2014; 41(11): 2286-2289.
47. European Medicines Agency. Annex 1: summary of product characteristics (Cimzia). Available from: www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/ WC500069763. pdf www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/ WC500069763. pdf. Accessed October 18, 2014.
48. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013; 11(3): 286-292; quiz e224.
49. Clowse ME, Wolf DC, Forger F, et al. Pregnancy outcomes in subjects exposed to certolizumab pegol. J Rheumatol. 2015; 42(12): 2270-2278.
50. Wakefield I, Stephens S, Foulkes R, Nesbitt A, Bourne T. The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab' monoclonal antibody. Toxicol Sci. 2011; 122(1): 170-176.
51. Marchioni RM, Lichtenstein GR. Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013; 19(17): 2591-2602.
52. Remicade (infliximab) prescribing information; 2013. Available from: http: //www. remicade. com/shared/product/remicade/prescribing-information. pdf. Accessed March 10, 2016.
53. Humira (adalimumab) prescribing information; 2014. Available from: http: //www. rxabbvie. com/pdf/humira. pdf. Accessed March 10, 2016.
54. Takeuchi T, Yamamoto K, Yamanaka H, et al. Post-hoc analysis showing better clinical response with the loading dose of Certolizumab pegol in Japanese patients with active rheumatoid arthritis. Mod Rheumatol. 2015: 1-26.
55. Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Mod Rheumatol. 2014; 24(5): 715-724.
56. Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Mod Rheumatol. 2014; 24(4): 552-560.